Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00264433 | A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent | PHASE2 | COMPLETED | - | — | — | - | - | Aug 6, 2007 | 11 | United States, Canada |
| NCT00421811 | A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan | PHASE1 | COMPLETED | 56 | — | — | Apr 1, 2007 | Mar 1, 2009 | Dec 28, 2010 | 7 | United States |
| NCT00390676 | A Study of ADH 1 in Combination With Carboplatin, or Docetaxel or Capecitabine | PHASE1 | COMPLETED | - | — | — | Nov 1, 2006 | Nov 1, 2009 | Dec 28, 2010 | 10 | United States |
| NCT00265057 | Study of ADH-1 Given Intravenously to Patients With Solid Tumors | PHASE1 | COMPLETED | - | — | — | Jun 1, 2005 | Jan 1, 2008 | Dec 28, 2010 | 3 | Italy, Switzerland |
| Name | Type | Description |
|---|---|---|
| ADH -1 (Exherin™) | DRUG | - |
| ADH-1 | DRUG | 4 gm IV Days 1 and 8 |
| melphalan | DRUG | By Isolated Limb Infusion (ILI), Lower Extremity: 7.5 mg/L (Limb Volume), Day 1 or Upper Extremity: 10 mg/L (Limb Volume), Day 1 |
| ADH -1 and carboplatin | DRUG | - |
| ADH -1 and docetaxel | DRUG | - |
| ADH -1 and capecitabine | DRUG | - |
Inclusion Criteria: * Signed written informed consent * Male and female patients \> or = 18 years of age with a solid tumor(s) refractory to standard curative therapy or for which no curative therapy exists * Histologically proven advanced and/or metastatic solid tumor of one of the following histo...